| Dr Francis F Kaveggia, MD | |
|
1000 Mineral Point Ave, Janesville, WI 53548-2940 | |
| (608) 741-6990 | |
| Not Available |
| Full Name | Dr Francis F Kaveggia |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 39 Years |
| Location | 1000 Mineral Point Ave, Janesville, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699833251 | NPI | - | NPPES |
| 30817400 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 28005 (Wisconsin) | Primary |
| 208800000X | Urology | (Illinois) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Health System Corp | Janesville, WI | Hospital |
| Mercy Walworth Hospital & Medical Center | Lake geneva, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mercy Health System Corporation | 7416860440 | 459 |
News Archive
A new study from the Center for Retirement Research at Boston College found that people "who enter retirement in good health are likely to pay more for medical expenses throughout the rest of their life than those who retire after developing a chronic condition," writes U.S. News & World Report.
The Hill reports that "Democratic leaders sent out a notice Monday morning alerting senators that when the chamber returns to session after the Thanksgiving holiday, 'roll call votes could occur at any time during the day and evening, with weekend sessions likely.'" The health bill is also likely to affect work on a climate change bill and some senators' plans to go to the climate summit in Copenhagen (Bolton, 11/23).
Idera Pharmaceuticals, Inc. today announced initiation of a Phase 1 clinical trial of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9.
Repeated radio-ablation therapy with iodine-131 to treat metastatic thyroid cancer can be less effective than the initial round of treatment due to de-differentiation of the cancer cells as the disease progresses, making them less sensitive to I-131.
The results of the first reported study of deep brain stimulation (DBS) in an animal model for temporal lobe epilepsy (TLE) presented today at the American Epilepsy Society (AES) 66th Annual Meeting suggests that DBS may have potential as therapy for this common and often difficult to treat form of epilepsy.
› Verified 1 days ago
| Entity Name | Mercy Health System Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598718603 PECOS PAC ID: 7416860440 Enrollment ID: O20031113000164 |
News Archive
A new study from the Center for Retirement Research at Boston College found that people "who enter retirement in good health are likely to pay more for medical expenses throughout the rest of their life than those who retire after developing a chronic condition," writes U.S. News & World Report.
The Hill reports that "Democratic leaders sent out a notice Monday morning alerting senators that when the chamber returns to session after the Thanksgiving holiday, 'roll call votes could occur at any time during the day and evening, with weekend sessions likely.'" The health bill is also likely to affect work on a climate change bill and some senators' plans to go to the climate summit in Copenhagen (Bolton, 11/23).
Idera Pharmaceuticals, Inc. today announced initiation of a Phase 1 clinical trial of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9.
Repeated radio-ablation therapy with iodine-131 to treat metastatic thyroid cancer can be less effective than the initial round of treatment due to de-differentiation of the cancer cells as the disease progresses, making them less sensitive to I-131.
The results of the first reported study of deep brain stimulation (DBS) in an animal model for temporal lobe epilepsy (TLE) presented today at the American Epilepsy Society (AES) 66th Annual Meeting suggests that DBS may have potential as therapy for this common and often difficult to treat form of epilepsy.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Francis F Kaveggia, MD 1000 Mineral Point Ave, Janesville, WI 53548-2940 Ph: (608) 741-6990 | Dr Francis F Kaveggia, MD 1000 Mineral Point Ave, Janesville, WI 53548-2940 Ph: (608) 741-6990 |
News Archive
A new study from the Center for Retirement Research at Boston College found that people "who enter retirement in good health are likely to pay more for medical expenses throughout the rest of their life than those who retire after developing a chronic condition," writes U.S. News & World Report.
The Hill reports that "Democratic leaders sent out a notice Monday morning alerting senators that when the chamber returns to session after the Thanksgiving holiday, 'roll call votes could occur at any time during the day and evening, with weekend sessions likely.'" The health bill is also likely to affect work on a climate change bill and some senators' plans to go to the climate summit in Copenhagen (Bolton, 11/23).
Idera Pharmaceuticals, Inc. today announced initiation of a Phase 1 clinical trial of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9.
Repeated radio-ablation therapy with iodine-131 to treat metastatic thyroid cancer can be less effective than the initial round of treatment due to de-differentiation of the cancer cells as the disease progresses, making them less sensitive to I-131.
The results of the first reported study of deep brain stimulation (DBS) in an animal model for temporal lobe epilepsy (TLE) presented today at the American Epilepsy Society (AES) 66th Annual Meeting suggests that DBS may have potential as therapy for this common and often difficult to treat form of epilepsy.
› Verified 1 days ago
Mitchell A Kopnick, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 3200 E Racine St, Janesville, WI 53546 Phone: 608-371-8000 Fax: 608-371-8930 |